ABPI welcomes the plenary vote by the European Parliament on the ‘Falsified Medicines Directive’.
Director General of the ABPI Dr Richard Barker said:
“This vote clears the way for concrete measures to help protect patients in Europe from counterfeit medicines which endanger the health and lives of patients. Implementation of the Directive will require the involvement of all key stakeholders – manufacturers, pharmacists and wholesalers but also patients – to ensure success. With their involvement in the design, implementation and running of systems, we can deliver the highest possible level of patient safety, the fastest rollout in member states at optimal possible cost.”
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064 Email: [email protected]
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.